

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

APOTEX INC.,  
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,  
Patent Owner

---

*Inter Partes* Review No.: IPR2022-01524

---

U.S. Patent No. 11,253,572  
Filed: June 21, 2021  
Issued: February 22, 2022  
Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT  
ANGIOGENIC EYE DISORDERS

---

**PETITION FOR *INTER PARTES* REVIEW  
OF U.S. PATENT NO. 11,253,572**

## TABLE OF CONTENTS

EXHIBIT LIST .....	iv
I. INTRODUCTION .....	1
II. MANDATORY NOTICES (37 C.F.R. § 42.8) .....	2
A. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1)).....	2
B. RELATED MATTERS (37 C.F.R. § 42.8(b)(2)) .....	2
C. LEAD AND BACK-UP COUNSEL AND SERVICE INFORMATION (37 C.F.R. § 42.8(b)(3)-(4)) .....	4
III. PAYMENT UNDER 37 C.F.R. § 42.15(a) AND § 42.103 .....	5
IV. GROUNDS FOR STANDING (37 C.F.R. § 42.104(a)).....	5
V. THE BOARD SHOULD NOT EXERCISE ITS DISCRETION TO DENY INSTITUTION.....	6
VI. THRESHOLD REQUIREMENT FOR <i>INTER PARTES</i> REVIEW .....	11
VII. OVERVIEW OF CHALLENGE AND PRECISE RELIEF REQUESTED.	11
A. CHALLENGED CLAIMS .....	11
B. STATUTORY GROUNDS OF CHALLENGE .....	12
VIII. OVERVIEW OF THE ‘572 PATENT .....	13
A. THE ‘572 PATENT.....	13
IX. CLAIM CONSTRUCTION (37 C.F.R. § 42.104(b)(3)).....	15
A. “INITIAL DOSE,” “SECONDARY DOSE,” AND “TERTIARY DOSE” .....	16
B. “4 WEEKS” AND “8 WEEKS,” AFTER THE IMMEDIATELY PRECEDING DOSE .....	17
C. “WHEREIN THE PATIENT ACHIEVES/GAINS...” .....	17

D.	“WHEREIN EXCLUSION CRITERIA FOR THE PATIENT INCLUDE BOTH OF...”	20
1.	The “Exclusion Criteria” are entitled no patentable weight under the printed matter doctrine	20
2.	The Board should apply the printed matter doctrine as part of its claim construction analyses	22
X.	PERSON OF ORDINARY SKILL IN THE ART	23
XI.	THE SCOPE AND CONTENT OF THE PRIOR ART	24
A.	TECHNOLOGY BACKGROUND	24
B.	PETITIONER’S PRIOR ART REFERENCES	26
1.	Dixon (Ex.1006)	27
2.	Regeneron (8-May-2008) (Ex.1009)	28
3.	NCT-795 (Ex.1010)	29
4.	NCT-377 (Ex.1011)	31
5.	Hecht (Ex.1025)	33
XII.	GROUNDS FOR UNPATENTABILITY	33
A.	ANTICIPATION	33
1.	Legal standards	34
2.	Ground 1: Dixon anticipates Claims 1-5, 8-11, 14, and 26-30	35
3.	Ground 2: Regeneron (8-May-2008) anticipates Claims 1-5, 8-11, 14, and 26-30	48
4.	Grounds 3 and 4: NCT-795 and NCT-377 each anticipate Claims 1-5, 8-11, 14, and 26-30	58
B.	OBVIOUSNESS	68

1.	Ground 5: Claims 6, 7, 12, and 13 are obvious over Dixon, or Regeneron (8-May-2008), or NCT-795, or NCT-377 in combination with Hecht .....	69
2.	No secondary considerations .....	71
XIII.	CONCLUSION.....	72
	CERTIFICATE OF SERVICE .....	74
	CERTIFICATE OF COMPLIANCE.....	75

## EXHIBIT LIST

Exhibit	Description
1001	U.S. Patent No. 11,253,572 (“572 patent”)
1002	Declaration of Angelo P. Tanna, M.D.
1003	Curriculum Vitae of Angelo P. Tanna, M.D.
1004	Jocelyn Holash et al., <i>VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects</i> , 99 PROC. NAT’L ACAD. SCI. 11393 (2002) (“Holash”)
1005	Quan Dong Nguyen et al., <i>A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration</i> , 116 OPHTHALMOLOGY 2141 (2009) (“Nguyen-2009”)
1006	James A. Dixon et al., <i>VEGF Trap-Eye for the Treatment of Neovascular Age-Related Macular Degeneration</i> , 18 EXPERT OPINION ON INVESTIGATIONAL DRUGS 1573 (2009) (“Dixon”)
1007	Adis R&D Profile, <i>Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye</i> , 9 DRUGS R&D 261 (2008) (“Adis”)
1008	F. Semeraro et al., <i>Aflibercept in Wet AMD: Specific Role and Optimal Use</i> , 7 DRUG DESIGN, DEV. & THERAPY 711 (2013) (“Semeraro”)
1009	Press Release, Regeneron, Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration (May 8, 2008), <a href="http://investor.regeneron.com/releasedetail.cfm?ReleaseID=394065">http://investor.regeneron.com/releasedetail.cfm?ReleaseID=394065</a> (“Regeneron (8-May-2008)”)
1010	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW1), NCT00509795, ClinicalTrials.gov (Apr. 28, 2009), <a href="https://clinicaltrials.gov/ct2/show/NCT00509795">https://clinicaltrials.gov/ct2/show/NCT00509795</a> (“NCT-795”)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.